FDA's commitment to transparency

被引：0

|

作者：

Guharoy, Roy ^{[1
,2
]}

Krenzelok, Edward ^{[3
]}

机构：

[1] Baptist Hlth, Dept Pharm, Montgomery, AL 36117 USA

[2] Univ Massachusetts, Sch Med, Montgomery, AL 36117 USA

[3] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2021年 / 78卷 / 17期

关键词：

D O I：

10.1093/ajhp/zxab053

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：1550 / 1551

页数：2

相关论文

共 50 条

[1] The Obama Administration's Commitment to Transparency: A Progress Report
Lichtblau, Eric
SOCIAL RESEARCH, 2010, 77 (03): : 975 - 980
[2] Commitment to integrity and transparency in research
Garcia de Lima, Regina Aparecida
Carnio, Evelin Capellari
REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2020, 28
[3] Increasing transparency at the FDA: The impact of the FDA Amendments Act of 2007
Wood, Susan F.
Perosino, Kristen L.
PUBLIC HEALTH REPORTS, 2008, 123 (04) : 527 - 530
[4] 2005 and beyond: Prizer's commitment to organizational transparency in clinical trials
Berelowitz, M
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S5 - S5
[5] Gifted Child Quarterly's Commitment to Transparency, Openness, and Research Improvement
Adelson, Jill L.
Matthews, Michael S.
GIFTED CHILD QUARTERLY, 2019, 63 (02) : 83 - 85
[6] FDA's decision on plan B: A surrogate for lack of commitment to women's health
Merkatz, RB
JOURNAL OF WOMENS HEALTH, 2005, 14 (09) : 860 - 860
[7] A Tale of Two Transparency Attempts at FDA
Tai, Laurence
FOOD AND DRUG LAW JOURNAL, 2013, 68 (04) : 423 - 447
[8] FDA Seeks Transparency in Data and Decisions
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2010, 23 (07) : 18 - 19
[9] FDA Transparency in an Inescapably Political World
Carpenter, Daniel
JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 29 - 32
[10] Commentary: Data monitoring confidentiality and FDA transparency
London, Alex John
CLINICAL TRIALS, 2015, 12 (01) : 12 - 14

← 1 2 3 4 5 →